Daprodustat Market to Reach USD 953.48 Million by 2036 as Rising Renal Anemia Treatment Adoption and Oral HIF-PHI Therapies

NEWARK, Del., July 15, 2026 - The global Healthcare industry is witnessing significant advancements in chronic kidney disease (CKD) management as demand for innovative oral therapies for renal anemia continues to rise worldwide. According to Future Market Insights (FMI), the global Daprodustat Market is projected to grow from USD 407.16 million in 2026 to USD 953.48 million by 2036, registering a CAGR of 8.9% during the forecast period. Expanding adoption of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), increasing prevalence of chronic kidney disease, and growing pharmaceutical investments in oral anemia therapies are expected to drive sustained market expansion.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-33615

The market is projected to generate an absolute dollar opportunity of approximately USD 546.32 million between 2026 and 2036. Rising demand for traceable pharmaceutical APIs, increasing commercialization of oral renal anemia therapies, and expanding regulatory approvals continue to strengthen long-term growth prospects.

Key Daprodustat Market Highlights at a Glance

· Market Size (2026): USD 407.16 Million

· Forecast Market Size (2036): USD 953.48 Million

· Forecast Period: 2026-2036

· CAGR (2026-2036): 8.9%

· Absolute Dollar Opportunity: Approximately USD 546.32 Million

· Leading Sales Channel: Direct Supply (69.0% Market Share in 2026)

· Leading Form: Powder (62.4% Market Share in 2026)

· Leading Purity Grade: 99.5% and Above (59.2% Market Share in 2026)

· Fastest-growing Country: China (10.6% CAGR through 2036)

· Second Fastest-growing Country: Japan (9.7% CAGR through 2036)

· Key Segments Covered: Form, Purity Grade, Application, Sales Channel, Buyer Type, Region

· Report Pages: 250

· Last Updated: June 30, 2026

· Reviewed by: Anurag Sharma

Why Is the Daprodustat Market Growing?

The market is expanding steadily as oral HIF-PHI therapies gain wider acceptance for treating anemia associated with chronic kidney disease. Growing demand for convenient oral alternatives to injectable erythropoiesis-stimulating agents (ESAs), along with increasing regulatory approvals and improved patient access, continues to support market growth.

Key Growth Drivers

· Rising prevalence of chronic kidney disease worldwide.

· Increasing incidence of renal anemia.

· Growing adoption of oral HIF-PHI therapies.

· Expanding regulatory approvals for Daprodustat.

· Rising demand for high-quality pharmaceutical APIs.

· Increasing investments in nephrology therapeutics.

· Growing emphasis on traceable pharmaceutical supply chains.

· Expanding commercialization of oral renal anemia treatments.

As healthcare systems increasingly prioritize patient-friendly oral therapies, demand for Daprodustat continues to strengthen across regulated pharmaceutical markets.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-33615

According to Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights, "Daprodustat is emerging as a strategically important therapy within the renal anemia treatment landscape. As oral HIF-PHI adoption expands globally, pharmaceutical buyers increasingly prioritize suppliers offering consistent manufacturing quality, comprehensive regulatory documentation, and dependable commercial-scale supply capabilities."

Which Sales Channel Leads the Daprodustat Market?

Direct Supply remains the dominant sales channel, accounting for 69.0% of global market revenue in 2026.

Pharmaceutical manufacturers increasingly prefer direct procurement agreements to ensure regulatory compliance, quality assurance, supply continuity, and transparent manufacturing documentation.

Sales Channel Highlights

· Direct supply dominates commercial procurement.

· Regulatory documentation supports buyer qualification.

· Long-term quality agreements improve supply reliability.

· Traceable API sourcing strengthens regulatory compliance.

Why Does Powder Form Dominate the Market?

Powder accounts for 62.4% of the global market in 2026 owing to its compatibility with oral solid dosage manufacturing, excellent blending characteristics, and efficient tablet compression performance.

Manufacturers continue utilizing powder APIs to support consistent production quality and large-scale commercial tablet manufacturing.

Form Segment Highlights

· Powder remains the preferred pharmaceutical form.

· Superior blending improves manufacturing consistency.

· Oral tablet production drives sustained demand.

· High-volume manufacturing enhances commercial scalability.

👉 Explore the Latest Pharmaceutical Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/pharmaceuticals

How Are High-Purity APIs Supporting Market Expansion?

99.5% and Above Purity Grade represents 59.2% of market demand in 2026 as pharmaceutical manufacturers increasingly prioritize impurity control, regulatory compliance, and product consistency for commercial drug production.

Purity Grade Highlights

· High-purity APIs dominate commercial manufacturing.

· Stringent quality standards strengthen supplier selection.

· Regulatory compliance supports global approvals.

· Consistent manufacturing enhances long-term procurement.

Market Dynamics

Market Drivers

Growing chronic kidney disease prevalence, expanding oral HIF-PHI adoption, increasing renal anemia treatment programs, rising pharmaceutical API demand, growing regulatory approvals, and expanding nephrology care continue driving market growth.

Market Restraints

Strict regulatory compliance requirements, pricing pressures, complex pharmaceutical approval processes, limited awareness in developing markets, and manufacturing qualification requirements continue posing challenges.

Market Trends

Innovation continues transforming renal anemia therapeutics.

Major trends include:

· Expansion of oral HIF-PHI therapies.

· Growing investment in nephrology drug development.

· Increasing emphasis on API traceability.

· Rising adoption of quality-by-design manufacturing.

· Expansion of commercial pharmaceutical partnerships.

· Growing focus on supply chain resilience and regulatory transparency.

Regional and Country Outlook

Asia continues leading global market expansion owing to increasing chronic kidney disease prevalence, expanding pharmaceutical manufacturing, and growing adoption of oral renal anemia therapies.

China is projected to remain the fastest-growing market with a 10.6% CAGR through 2036, supported by increasing HIF-PHI approvals, rising CKD treatment demand, and expanding pharmaceutical production capacity.

Japan follows with a 9.7% CAGR, driven by well-established renal anemia treatment protocols, growing commercial adoption of HIF-PHI therapies, and advanced healthcare infrastructure.

North America and Europe continue to generate steady demand through increasing nephrology treatment adoption, regulatory approvals, and growing investments in innovative renal care.

Competitive Landscape

Competition remains focused on manufacturing excellence, regulatory compliance, high-purity API production, and dependable commercial supply capabilities to strengthen long-term customer relationships.

Key Companies

· GSK

· Kyowa Kirin

· MSN Laboratories

· Hetero Drugs

· MetroChem API

· Laurus Labs

· Aurobindo Pharma

· WuXi STA

· CordenPharma

👉 Read Full Report:
https://www.futuremarketinsights.com/reports/daprodustat-market

Frequently Asked Questions

1. What is the projected size of the Daprodustat Market by 2036?

The global Daprodustat Market is projected to reach USD 953.48 million by 2036, growing from USD 407.16 million in 2026.

2. What is the expected CAGR of the Daprodustat Market?

The market is forecast to expand at a CAGR of 8.9% between 2026 and 2036.

3. Which sales channel dominates the market?

Direct Supply leads the market, accounting for 69.0% of total revenue in 2026.

4. Which form holds the largest market share?

Powder remains the leading form, capturing 62.4% of the market in 2026.

5. What factors are driving market growth?

Growing prevalence of chronic kidney disease, increasing adoption of oral HIF-PHI therapies, expanding renal anemia treatment programs, rising demand for high-purity pharmaceutical APIs, and increasing regulatory approvals continue driving global market growth.

Related Reports

Self Testing Market - https://www.futuremarketinsights.com/reports/self-testing-market

Cell Culture Media Market - https://www.futuremarketinsights.com/reports/cell-culture-media-market

Cartilage Repair Market - https://www.futuremarketinsights.com/reports/cartilage-repair-market

Magnetic Resonance Imaging Coils Market - https://www.futuremarketinsights.com/reports/magnetic-resonance-imaging-coils-market

Rare Neurological Disease Treatment Market - https://www.futuremarketinsights.com/reports/rare-neurological-disease-treatment-market

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA
Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
Phone: +91 8600020075
For Media: Rahul.Singh@futuremarketinsights.com
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie® Award, and a member of the Greater New York Chamber of Commerce) provides deep insights into governing factors elevating demand in global markets.

FMI delivers market intelligence, consulting services, and syndicated research reports across chemicals, materials, food ingredients, pharmaceuticals, industrial manufacturing, sustainability, and advanced materials sectors.

With global expertise and industry-focused research capabilities, FMI provides actionable insights that help organizations understand market dynamics and identify emerging opportunities.

This release was published on openPR.